GURU.Markets stock price, segment price, and overall market index valuation
The company's share price 22nd Century Group
22nd Century Group is a biotech company specializing in reducing nicotine levels in tobacco and cannabinoids in cannabis. Its stock price is a bet on regulatory changes that could require the use of its technologies.
Share prices of companies in the market segment - Narco food
22nd Century Group is a biotech company that uses genetic engineering to reduce nicotine levels in tobacco and alter cannabinoid levels in cannabis. We've classified it as a "Narco-Food" company. The chart below shows the dynamics of this innovative, yet controversial, sector.
Broad Market Index - GURU.Markets
22nd Century Group is a biotechnology company that uses genetic engineering to reduce nicotine levels in tobacco and alter cannabinoid levels in hemp. It is a component of the GURU.Markets index. The chart below represents the market. See how this company's stock compares to the agricultural sector.
Change in the price of a company, segment, and market as a whole per day
XXII - Daily change in the company's share price 22nd Century Group
22nd Century Group, Inc.'s daily stock price fluctuates reflecting the volatility of the tobacco and cannabis industries. The metric demonstrates sensitivity to regulatory news and demand for its low-nicotine tobacco products.
Daily change in the price of a set of shares in a market segment - Narco food
22nd Century Group uses biotechnology to modify plants, primarily to create low-nicotine tobacco. The chart below shows the average volatility in this niche and highly regulated industry, allowing one to compare the risks and dynamics of 22nd Century Group with the overall trends of its unique market.
Daily change in the price of a broad market stock, index - GURU.Markets
22nd Century Group is an agritech company that uses genetic engineering to reduce nicotine levels in tobacco and alter cannabinoid levels in hemp. Its shares are volatile and dependent on regulatory decisions and market acceptance of its products.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization 22nd Century Group
For 22nd Century Group, year-over-year performance is the story of its plant biotech platform. Its 12-month market cap is entirely dependent on regulatory decisions, particularly the FDA mandate to reduce nicotine in cigarettes. The success of its low-nicotine cigarettes could fundamentally change the entire tobacco industry.
Annual dynamics of market capitalization of the market segment - Narco food
22nd Century Group is a unique biotechnology company that uses genetic engineering to reduce nicotine levels in tobacco. Its stock price is extremely volatile, reflecting investor confidence in its breakthrough potential and its dependence on FDA regulatory decisions.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
22nd Century Group, a biotech company that genetically engineers tobacco and hemp plants to reduce nicotine levels and optimize cannabinoids, is at the intersection of healthcare and agriculture. Its year-over-year market capitalization reflects regulatory changes and public demand for less harmful products.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization 22nd Century Group
22nd Century Group is a biotech company focused on tobacco harm reduction. Its monthly performance is entirely dependent on the commercial success of its ultra-low-nicotine cigarettes and FDA regulatory decisions, which could either open or close the market for it.
Monthly dynamics of market capitalization of the market segment - Narco food
22nd Century Group is a biotechnology company that uses genetic engineering to grow tobacco with very low nicotine levels. Its goal is to offer less harmful cigarettes. Success depends on regulatory approval and market acceptance. The dynamics of the tobacco sector reflect the general trends against which 22nd Century is attempting to create a new product category.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
22nd Century Group is a biotech company working to reduce nicotine levels in tobacco and modify cannabinoid levels in hemp. Its shares are driven by news of regulatory decisions (such as from the FDA) and advances in agricultural technology. Its correlation with the market is weak, placing it on regulatory changes and biotechnology.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization 22nd Century Group
22nd Century Group is a biotech company that uses genetic engineering to reduce the nicotine content of tobacco and alter the cannabinoid profile of cannabis. Its weekly stock price reflects FDA decisions and regulatory changes related to these regulated products.
Weekly dynamics of market capitalization of the market segment - Narco food
22nd Century Group uses biotechnology to alter nicotine levels in tobacco and cannabinoids in cannabis. Its business operates at the intersection of science and regulation. This chart helps you understand how news in these two areas impacts the company's stock, separate from general consumer trends.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
22nd Century Group is a biotech company focused on tobacco and cannabis. Its shares are driven by regulatory news and scientific developments. The chart will show how disconnected its performance is from the broader market and how it operates according to its own, highly volatile rules.
Market capitalization of the company, segment and market as a whole
XXII - Market capitalization of the company 22nd Century Group
22nd Century Group's market capitalization chart reflects investors' valuation of its plant biotech platform. Its dynamics reflect its efforts to commercialize ultra-low-nicotine cigarettes and breed cannabis with targeted traits. Its low valuation reflects both its potential and the regulatory and commercial hurdles.
XXII - Share of the company's market capitalization 22nd Century Group within the market segment - Narco food
22nd Century Group is a biotech company that uses genetic engineering to alter the nicotine content of tobacco and the cannabinoid content of hemp. Its market share is small, but it is a unique technological player. Its market capitalization is driven by its reduced-risk tobacco and specialized cannabis strains.
Market capitalization of the market segment - Narco food
Below is a graph showing the total value of the entire tobacco and agricultural sector. For 22nd Century Group, with its unique technology for growing low-nicotine tobacco, this line is a map of the industry's future. Its dynamics illustrate how technology is attempting to reduce the harm from traditional products, which is the core of the company's business model.
Market capitalization of all companies included in a broad market index - GURU.Markets
22nd Century Group is a biotechnology company that uses genetic engineering to alter the nicotine content of tobacco and the cannabinoid content of cannabis. Its market capitalization reflects the value of its unique and controversial technology.
Book value capitalization of the company, segment and market as a whole
XXII - Book value capitalization of the company 22nd Century Group
22nd Century Group is a biotech company that modifies the nicotine levels in tobacco and the cannabinoid levels in hemp. Its book value is derived from its patents, R&D centers, and production facilities. This is its "genetic" foundation. How has it evolved? The chart below tells the story.
XXII - Share of the company's book capitalization 22nd Century Group within the market segment - Narco food
22nd Century Group is a plant-based biotechnology company. Its business is based on unique physical assets: greenhouses, laboratories, and equipment for genetically modifying tobacco and hemp. The chart shows its share of specialized agritech infrastructure.
Market segment balance sheet capitalization - Narco food
22nd Century Group is a biotechnology company. Compared to the capital-intensive agricultural sector, its model is knowledge-intensive. The industry's asset chart reflects the value of farms, which 22nd Century doesn't own. Its capital comes from tobacco and hemp genetics.
Book value of all companies included in the broad market index - GURU.Markets
22nd Century Group's assets include unique plantations and technologies for growing tobacco with very low nicotine levels and hemp with a controlled cannabinoid profile. Its book value reflects its agro-tech potential aimed at reducing the harms of smoking.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - 22nd Century Group
22nd Century Group is a biotech company that genetically engineers plants to reduce the nicotine content of tobacco. Its market capitalization is a bet that its technology will be the key to creating less harmful cigarettes.
Market to book capitalization ratio in a market segment - Narco food
22nd Century Group is a biotech company that modifies nicotine levels in tobacco and cannabinoids in cannabis. The chart shows how investors view its unique technology and its potential to disrupt the traditional tobacco and cannabis industries.
Market to book capitalization ratio for the market as a whole
22nd Century Group uses biotechnology to modify the nicotine content of tobacco and the cannabis content of hemp. It's a unique combination of agritech and biotech. This chart helps us understand the premium the market is willing to pay for innovations that could fundamentally change regulated industries.
Debts of the company, segment and market as a whole
XXII - Company debts 22nd Century Group
22nd Century Group, a biotech company specializing in reducing nicotine levels in tobacco and altering cannabinoid levels in cannabis, requires significant capital for its R&D and lobbying efforts. This chart shows the company's long and capital-intensive journey in its quest to disrupt regulated industries.
Market segment debts - Narco food
22nd Century Group is a biotech company that uses genetic engineering to alter nicotine levels in tobacco and cannabinoids in hemp. The chart shows how the company is funding its R&D and attempting to commercialize its unique products, such as very low-nicotine cigarettes, which require complex regulatory procedures.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio 22nd Century Group
22nd Century Group is a biotechnology company that uses genetic engineering to alter the nicotine content of tobacco and the cannabinoid content of hemp. Such innovative developments in the agricultural sector require long-term investments in R&D. This chart shows how the company uses debt to fund its unique, yet capital-intensive, research.
Market segment debt to market segment book capitalization - Narco food
22nd Century Group is a biotechnology company that uses genetic engineering to alter the nicotine content of tobacco and the cannabinoid content of hemp. This chart shows how the company finances its unique research. It compares its debt load to the market capitalization of the entire agribusiness and biotechnology sector.
Debt to book value of all companies in the market
22nd Century Group is a biotech company that uses genetic engineering to reduce nicotine levels in tobacco and alter cannabinoid levels in hemp. This is a unique but capital-intensive niche. How heavily is the company reliant on debt? This chart of total debt in the market helps assess the riskiness of its innovative business model.
P/E of the company, segment and market as a whole
P/E - 22nd Century Group
22nd Century Group is a biotechnology company that uses genetic engineering to reduce nicotine levels in tobacco and alter cannabinoid levels in cannabis. This chart shows how investors value its unique technology. The valuation depends on regulatory decisions and the commercialization of its products.
P/E of the market segment - Narco food
22nd Century Group is a biotech company that uses genetic engineering to alter nicotine levels in tobacco and cannabinoid levels in hemp. This chart reflects the average valuation in the biotech sector, but takes into account the specifics and regulatory risks associated with the tobacco and cannabis industries.
P/E of the market as a whole
22nd Century Group, Inc. is a biotechnology company that uses genetic engineering to alter nicotine levels in tobacco and cannabinoid levels in hemp. This chart reflects overall investor interest in the cannabis and biotech sectors. It helps understand how the market is assessing 22nd Century Group's unique technology amid regulatory changes and overall market sentiment.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company 22nd Century Group
22nd Century Group is a biotechnology company specializing in reducing nicotine levels in tobacco and modifying cannabinoid levels in cannabis. This chart shows how investors view the future of tobacco regulation and the potential of engineered plants for both harm reduction and therapeutic applications.
%20P%2FE%2022nd%20Century%20Group&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-22nd-Century-Group&v=1772640781339 "Chart of the company's future (projected) P/E 22nd Century Group")
Future (projected) P/E of the market segment - Narco food
22nd Century Group is a biotechnology company that uses genetic engineering to alter the nicotine content of tobacco and the cannabinoid content of cannabis. This chart compares the company's future profitability expectations with those of its sector. It helps understand how the market views its unique technology and its potential to create less harmful products.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Narco%20food&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Narco-food&v=1772640781343 "Future (projected) P/E graph of the market segment - Narco food")
Future (projected) P/E of the market as a whole
22nd Century Group is a biotech company that uses genetic engineering to alter nicotine levels in tobacco and cannabinoid levels in cannabis. This market sentiment chart reflects investor sentiment toward companies operating in the controversial but potentially huge tobacco and cannabis markets using advanced technologies.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772640781349 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit 22nd Century Group
22nd Century Group is a biotechnology company that uses genetic engineering to alter nicotine levels in tobacco and cannabinoid levels in hemp. Profits depend on the commercialization of its unique crops. This chart shows financial results at the intersection of agriculture, regulation, and healthcare.
Profit of companies in the market segment - Narco food
22nd Century Group is a biotech company that uses genetic engineering to alter the nicotine content of tobacco and the cannabinoid content of cannabis. This chart shows the overall profitability of the alternative products sector, where technology can help reduce the harms of smoking and create new cannabis-based therapeutic products.
Overall market profit
22nd Century Group is a biotechnology company specializing in reducing nicotine levels in tobacco and cannabinoids. Its business is dependent on changes in tobacco and cannabis industry regulation, as well as scientific developments. These factors are not related to the general economic cycles observed in this chart.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company 22nd Century Group
22nd Century Group is a biotechnology company specializing in reducing nicotine levels in tobacco and modifying cannabinoid levels in cannabis. Future profits depend on regulatory decisions and the commercialization of its unique crops. This chart reflects expectations for its breakthrough, yet risky, technologies.
%20profit%20of%20the%20company%2022nd%20Century%20Group&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-22nd-Century-Group&v=1772640781559 "Graph of future (projected) profit of the company 22nd Century Group")
Future (predicted) profit of companies in the market segment - Narco food
22nd Century Group is a biotechnology company that uses genetic engineering to reduce nicotine levels in tobacco and alter cannabinoid levels in cannabis. Its goal is to reduce the harms of smoking and create new herbal medicines. This chart shows expectations for the consumer goods sector, providing context for evaluating the company's innovations.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Narco%20food&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Narco-food&v=1772640781625 "Graph of future (predicted) profits of companies in a market segment - Narco food")
Future (predicted) profit of the market as a whole
22nd Century Group is a biotechnology company specializing in reducing nicotine levels in tobacco and modifying cannabinoid levels in hemp. Its success depends on regulatory decisions and market acceptance of its products. This economic outlook affects the overall investment climate for innovative but controversial industries.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772640781763 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - 22nd Century Group
22nd Century Group is a biotech company that uses genetic engineering to reduce nicotine levels in tobacco and alter cannabinoid levels in hemp. This chart shows how investors view its unique technology, which has the potential to revolutionize the tobacco and cannabis industries.
P/S market segment - Narco food
22nd Century Group is a biotech company that uses genetic engineering to alter nicotine levels in tobacco plants. Their very low-nicotine cigarettes may help smokers reduce their addiction. This chart shows the average revenue estimate for the sector, which helps assess how the market views this innovation within the tobacco industry.
P/S of the market as a whole
22nd Century Group is a biotech company that uses genetic engineering to alter nicotine levels in tobacco and cannabinoid levels in hemp. This chart helps understand how the market values this innovative company, whose technologies have the potential to revolutionize the tobacco and cannabis industries, despite regulatory risks.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company 22nd Century Group
22nd Century Group is a biotechnology company that uses genetic engineering to reduce nicotine levels in tobacco and alter cannabinoid levels in cannabis. Its future revenue valuation is critical, reflecting investors' confidence in its ability to commercialize reduced-risk tobacco products and unique cannabis strains for medical and recreational use.
%20P%2FS%2022nd%20Century%20Group&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-22nd-Century-Group&v=1772640782014 "The graph of the company's future (projected) P/S 22nd Century Group")
Future (projected) P/S of the market segment - Narco food
22nd Century Group is a biotech company that uses genetic engineering to reduce nicotine levels in tobacco and alter cannabinoid levels in hemp. This chart compares the company's estimated future revenue with other agritech and tobacco companies. It reflects investor expectations regarding the commercialization of its low-nicotine cigarettes.
%20P%2FS%20market%20segment%20graph%20-%20Narco%20food&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Narco-food&v=1772640782052 "Future (projected) P/S market segment graph - Narco food")
Future (projected) P/S of the market as a whole
22nd Century Group is a biotechnology company that uses genetic engineering to alter the nicotine content of tobacco and the cannabinoid content of cannabis. Its future depends on regulatory decisions and demand for reduced-risk products. This graph of investor expectations reflects their views on innovation in the tobacco and cannabis industries.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772640782062 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales 22nd Century Group
This chart shows the revenue of 22nd Century Group, a biotechnology company that uses genetic engineering to reduce nicotine levels in tobacco and alter cannabinoid levels in cannabis. Revenue is generated from sales of reduced-nicotine cigarettes and from licensing its technology.
Sales of companies in the market segment - Narco food
22nd Century Group is a biotechnology company that uses genetic engineering to alter nicotine levels in tobacco and cannabinoid levels in hemp. Its revenue breakdown includes revenue from sales of reduced-nicotine cigarettes and potential revenue from licensing its technologies to the pharmaceutical and agricultural industries.
Overall market sales
22nd Century Group is a biotechnology company that uses genetic engineering to alter the nicotine content of tobacco and the cannabinoid content of cannabis. The company aims to reduce the harm of smoking. This general economics chart does not reflect the specifics of its business, which is dependent on regulatory decisions and changing public attitudes toward nicotine consumption.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company 22nd Century Group
22nd Century Group is a biotechnology company that uses genetic engineering to alter nicotine levels in tobacco and cannabinoids in hemp. Future revenue depends on the commercialization of its reduced-nicotine tobacco and other products. This chart reflects analyst expectations for demand for reduced-risk products.
%20sales%20of%20the%20company%2022nd%20Century%20Group&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-22nd-Century-Group&v=1772640782189 "Schedule of future (projected) sales of the company 22nd Century Group")
Future (projected) sales of companies in the market segment - Narco food
22nd Century Group uses biotechnology to reduce the nicotine content of tobacco, creating reduced-risk cigarettes. This chart shows the forecast for the tobacco industry. How are regulatory trends and demand for less harmful alternatives affecting analysts' expectations? This reflects the potential for innovation in the sector.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Narco%20food&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Narco-food&v=1772640782243 "Schedule of future (projected) sales of companies in the market segment - Narco food")
Future (projected) sales of the market as a whole
22nd Century Group is a biotechnology company specializing in reducing nicotine levels in tobacco and modifying cannabinoid levels in cannabis. Demand for its products depends on regulatory decisions (such as those from the FDA) and consumer trends toward less harmful products. This timeline is less important than the regulatory environment, which could completely reshape its markets.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772640782323 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality 22nd Century Group
22nd Century Group is a biotech company that uses genetic engineering to alter nicotine levels in tobacco and cannabinoids in cannabis. This graph shows its path to commercialization. Profitability depends on regulatory approvals for ultra-low-nicotine cigarettes and successful licensing of its technologies.
Market segment marginality - Narco food
22nd Century Group, Inc. is a biotechnology company that uses genetic engineering to alter nicotine levels in tobacco and cannabinoid levels in hemp. This chart depicts its financial position, with profitability dependent on the commercialization of its reduced-nicotine tobacco and other products based on its unique technology.
Market marginality as a whole
22nd Century Group uses plant biotechnology to reduce nicotine levels in tobacco and modify cannabinoid levels. The company operates at the intersection of science and regulated markets. This overall profitability chart reflects the state of these industries and their readiness for innovation that could fundamentally transform their products.
Employees in the company, segment and market as a whole
Number of employees in the company 22nd Century Group
22nd Century Group is a biotechnology company that uses genetic engineering to alter nicotine levels in tobacco and cannabinoids in hemp. Its team of scientists and agronomists is the backbone of its business. This chart shows how the company is investing in R&D to develop its unique crops and preparing to commercialize reduced-nicotine cigarettes.
Share of the company's employees 22nd Century Group within the market segment - Narco food
22nd Century Group is a biotechnology company that uses genetic engineering to alter the nicotine content of tobacco and the cannabinoid content of hemp. Its operations require a team of geneticists and agronomists. This chart shows the company's market share, reflecting its unique scientific approach and the scale of its research and breeding programs.
Number of employees in the market segment - Narco food
22nd Century Group is a biotechnology company that uses genetic engineering to alter nicotine levels in tobacco and cannabinoids in hemp. The chart shows its involvement in the specialty food sector. The company's technology enables the creation of tobacco products with reduced nicotine levels, which could aid in smoking cessation.
Number of employees in the market as a whole
22nd Century Group is a biotech company that uses genetic engineering to alter the nicotine content of tobacco and the cannabinoid content of cannabis. Its growth depends on regulatory decisions and market acceptance. This chart shows general trends, while XXII is an example of a company operating in controversial but potentially large new industries with unique employment dynamics.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company 22nd Century Group (XXII)
22nd Century Group is a biotech company that genetically modifies plants, primarily to create low-nicotine tobacco and optimize cannabis. Their value lies in R&D. This chart shows how the market values their unique IP. It reflects the market value per scientist, which is a bet on their agricultural technologies.
%20of%20the%20company%2022nd%20Century%20Group%20(XXII)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-22nd-Century-Group-XXII&v=1772640782745 "Chart of market capitalization per employee (in thousands of dollars) of the company 22nd Century Group (XXII)")
Market capitalization per employee (in thousands of dollars) in the market segment - Narco food
22nd Century Group (XXII) is a biotechnology company that uses genetic engineering to alter nicotine levels in tobacco and cannabinoid levels in hemp. This metric reflects the value of their unique ability to "program" plants. Their high market capitalization per employee speaks to the potential of their technology to completely transform the tobacco and cannabis industries.
%20by%20market%20segment%20-%20Narco%20food&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Narco-food&v=1772640782762 "Market capitalization per employee (in thousands of dollars) by market segment - Narco food")
Market capitalization per employee (in thousands of dollars) for the overall market
22nd Century Group is a biotech company that uses genetic engineering to grow tobacco with extremely low nicotine levels. The company's value lies in its unique technology. This chart shows how the market views the potential of its product to reduce the harms of smoking, which could radically change the tobacco industry.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772640782818 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company 22nd Century Group (XXII)
22nd Century Group is a biotech company that modifies plant genetics (low-nicotine tobacco, cannabis). It's a science-intensive R&D business. This chart reflects the company's stage: whether it's investing in scientists (loss per employee) or already profiting from licensing its technologies.
%20Chart%2022nd%20Century%20Group%20(XXII)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-22nd-Century-Group-XXII&v=1772640782888 "Company Profit Per Employee (in thousands of dollars) Chart 22nd Century Group (XXII)")
Profit per employee (in thousands of dollars) in the market segment - Narco food
22nd Century Group, Inc. is a biotechnology company working to reduce nicotine levels in tobacco and modify cannabinoid levels in cannabis. Their productivity per employee reflects their scientific breakthroughs and their commercial potential. The graph allows one to assess the potential of their unique technologies to transform the industry and generate profits.
%20in%20the%20market%20segment%20-%20Narco%20food&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Narco-food&v=1772640782897 "Chart of profit per employee (in thousands of dollars) in the market segment - Narco food")
Profit per employee (in thousands of dollars) for the market as a whole
22nd Century Group is a biotech company working with plants. They use genetic engineering to reduce nicotine levels in tobacco (for less harmful cigarettes) and to optimize cannabis. This graph shows how agribusiness, at the intersection of R&D and requiring both scientists and agronomists, compares in terms of personnel efficiency.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772640782926 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee 22nd Century Group (XXII)
22nd Century Group is involved in plant biotechnology, specifically the creation of low-nicotine tobacco. This chart shows how successfully the company is commercializing its unique developments. Increasing revenue per employee will indicate recognition of their products and increased sales amid tightening regulations.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-22nd-Century-Group-XXII&v=1772640782948 "Sales chart per company employee 22nd Century Group (XXII)")
Sales per employee in the market segment - Narco food
22nd Century Group (XXII) is an agritech company. They use genetic engineering to modify crops, primarily tobacco (with very low nicotine content) and cannabis. This graph shows the average output in the sector. For XXII, this is an indicator: how productive is their R&D team in commercializing (selling, licensing) these unique crops?
Sales per employee for the market as a whole
22nd Century Group is an agritech company. They use genetic engineering to modify plants, primarily to create tobacco with very low nicotine levels. Their core business is R&D, which measures the extent to which their scientific research translates into commercial sales.
Short shares by company, segment and market as a whole
Shares shorted by company 22nd Century Group (XXII)
22nd Century Group (XXII) uses biotechnology to alter the nicotine levels in tobacco (creating very low-dose cigarettes) and the cannabinoid levels in hemp. This chart shows the number of short positions. Short sellers may be betting that regulators (like the FDA) won't approve its products or that consumers simply won't want to smoke "nicotine-free" tobacco.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-22nd-Century-Group-XXII&v=1772640783005 "Short Shares Chart for the Company 22nd Century Group (XXII)")
Shares shorted by market segment - Narco food
22nd Century Group (XXII) is a biotech company that uses genetic engineering to modify plants. Their main product is cigarettes with very low nicotine levels. This chart shows the total short position volume across the entire tobacco sector. It reflects how pessimistic investors are about the entire industry.
Shares shorted by the overall market
22nd Century Group is involved in bioengineering tobacco and hemp (reducing nicotine/cannabinoid levels). This chart illustrates the overall market pessimism. Investors see enormous regulatory risks and dependence on FDA decisions. In times of fear, the market is unwilling to bet on complex and unpredictable regulatory battles.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator 22nd Century Group (XXII)
22nd Century Group is a biotech company that modifies plants (low-nicotine tobacco, cannabis). It's a risky business, dependent on regulators. This chart is the "pulse" of FDA decisions. It "overheats" on news of their product approvals and "cools" during the long months of waiting.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-22nd-Century-Group-XXII&v=1772640783240 "RSI 14 indicator chart for the company's stock 22nd Century Group (XXII)")
RSI 14 Market Segment - Narco food
22nd Century (XXII) is a biotech company that "edits" plants. They are known for creating very low-nicotine tobacco and working with cannabis. This chart measures the collective sentiment in the Cannabis/Tobacco sector. It shows when the entire industry is "overheated" or "oversold," which is the backdrop for XXII.
RSI 14 for the overall market
For 22nd Century Group, which works in tobacco R&D, this chart is an indicator of appetite for hype. During periods of market euphoria, investors are willing to generously finance speculative R&D projects of the "future." In moments of panic, capital flees unprofitable, "conceptual" projects, and companies risk being left without funds.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast XXII (22nd Century Group)
22nd Century Group is a biotech company that genetically modifies plants. Its flagship product is VLN cigarettes, which contain 95% less nicotine and are FDA-approved. This chart shows the speculative average price target from analysts, based on their belief in the commercial success of this "non-addictive" cigarette.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-XXII-22nd-Century-Group&v=1772640783492 "A chart showing analyst consensus forecasts for the expected stock price. XXII (22nd Century Group)")
The difference between the consensus estimate and the actual stock price XXII (22nd Century Group)
22nd Century is an agro-biotech company. The company genetically modifies plants, creating tobacco with *ultra-low* nicotine levels (FDA-approved) and hemp with *zero* THC. This chart illustrates the analyst community's opinion on the company's future. It measures the distance between the stock price and the target, reflecting their faith in this "disruptive" technology.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-XXII-22nd-Century-Group&v=1772640783546 "A chart showing the difference between the consensus forecast and the actual stock price. XXII (22nd Century Group)")
Analyst consensus forecast for stock prices by market segment - Narco food
22nd Century Group (XXII) is a biotechnology company that genetically modifies plants (tobacco, hemp) to reduce nicotine levels or increase cannabinoid levels. This chart shows general expectations for the tobacco sector. It reflects whether experts believe in the future of "safe" tobacco.
Analysts' consensus forecast for the overall market share price
22nd Century Group is an agritech company. They use genetic engineering to modify plants, creating tobacco with very low nicotine levels (for "safe" cigarettes) and cannabis. This chart shows the overall "risk appetite" in the market. For XXII, which operates at the intersection of biotech and the speculative "narcotics" sector, overall market optimism (risk appetite) is critical for funding.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index 22nd Century Group
22nd Century Group (XXII) is biotechnology for vice. Their specialty is genetically modified plants: tobacco with very low nicotine levels (for safe cigarettes) and hemp with a specific cannabinoid profile. This chart is a summary indicator of their R&D efforts. It reflects their (slow) path to commercialization and their dependence on regulators (the FDA).
AKIMA Market Segment Index - Narco food
22nd Century Group (XXII) is an AgTech company that edits plants. Using biotechnology, they created very low nicotine (VLN) tobacco—the only FDA-approved tobacco. They are also working on hemp and hops. This chart shows the average index for the segment. It helps assess how this gene-agricultural model compares to the industry average.
The AKIM Index for the overall market
22nd Century Group is a plant-based biotech company focused on reducing nicotine levels in tobacco (VLN). It sold its cannabis business. This chart, which reflects the market average, provides a macro backdrop. It helps assess how 22nd Century Group, which is struggling to survive and regulate tobacco, compares to the overall situation.
